Diagenode

News

PRESS RELEASE
November 8, 2013

Diagenode Launches Extensively Validated Epigenetic Antibodies for Broad Research Use

Industry’s most highly validated antibodies as used by the BLUEPRINT Epigenome Consortium researchers are now broadly available for epigenetics researchers worldwide.

Diagenode, Inc., a leading global provider of complete solutions for epigenetics research, recently launched its “Premium” line of antibodies for epigenetics applications such as chromatin immunoprecipitation (ChIP) and DNA methylation. These antibodies have been extensively validated for high sensitivity and specificity through a multi-step process including assessment through ELISA, dot blot, peptide arrays, Western blot, IF, CHIP-qPCR, and ChIP-seq. They were initially developed in a collaborative effort for the well-known BLUEPRINT Epigenome consortium and now have been released for widespread research use.

 

Read more

Events

  • Virtual ChIP workshop - January 18-19, 2022 or January 25-26, 2022
    Diagenode
    Jan 18-Jan 26, 2022
  • Virtual DNA Methylation - January 18-19, 2022 or January 25-26, 2022
    Diagenode
    Jan 18-Jan 26, 2022
  • Lausanne Genomics Days 2022
    Lausanne, Switzerland
    Feb 14-Feb 15, 2022
 See all events

News

 See all news


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics